IDYA - IDEAYA Biosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.126B

Cash

339.5M

Avg Qtr Burn

-23.84M

Short % of Float

8.10%

Insider Ownership

1.72%

Institutional Own.

98.42%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Darovasertib (IDE196) (PKC Inhibitor) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Darovasertib Details Solid tumor/s, Cancer, Uveal melanoma	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE397 (MAT2A) Details Solid tumor/s, Cancer	Phase 1/2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IDE161 Details Solid tumor/s, Cancer, ER+/HER2- breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.